Friedreich Ataxia: Clinical Trials

36 trials for Friedreich Ataxia, newest first

ClinicalTrials Daily  ·  Areas  ·  Conditions  ·  Drugs  ·  Sponsors  ·  

29 completed, 3 recruiting, 1 active not recruiting, 1 not yet recruiting. 36 Phase 2, 8 Phase 1, 3 Phase 3.

By phase and status

PhaseTrialsStatus
Phase 236Completed 29, Recruiting 3, Active not recruiting 1, Not yet recruiting 1, Terminated 1, Withdrawn 1
Phase 18Completed 6, Active not recruiting 1, Recruiting 1
Phase 33Completed 2, Terminated 1

Follow Friedreich Ataxia: new trials by email Literature Review of Friedreich Ataxia trials Research Report on Friedreich Ataxia

Trials (filtered) newest first · largest first

All 36 trials

Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.

TrialPhaseStatusSponsorEnrollmentStartUpdated
GV101 for Friedreich's Ataxia (FA) Treatment
GV101, Placebo - Friedreich's Ataxia
Phase 2Not yet recruitingGraviton Bioscience Corporation482026-11-012026-10-15
Study of LX2006 Gene Therapy in Friedreich Ataxia Cardiomyopathy
LX2006, Usual Care - Friedreich Ataxia, Cardiomyopathy, Secondary
Phase 2RecruitingLexeo Therapeutics262026-06-252026-11-17
A Multiple Ascending Dose Study of DT-216P2 in Patients With Friedreich's Ataxia
DT-216P2 - Friedreich Ataxia
Phase 1 / Phase 2RecruitingDesign Therapeutics, Inc.202025-06-012025-05-18
An Open-Label Study of CTI-1601 in Subjects With Friedreich's Ataxia
CTI-1601 - Friedreich Ataxia
Phase 2RecruitingLarimar Therapeutics, Inc.852024-01-252026-10-27
Study of the Efficacy and Safety of Nicotinamide in Patients With Friedreich Ataxia
Nicotinamide, Placebo - Friedreich Ataxia
Phase 2WithdrawnRWTH Aachen University2023-04-012024-01-24
A Study of Vatiquinone for the Treatment of Participants With Friedreich Ataxia
Vatiquinone - Friedreich Ataxia
Phase 2CompletedPTC Therapeutics52022-10-122025-08-22
A Double-Blind, Placebo-Controlled, Dose Exploration Study of CTI-1601 in Adult Subjects With Friedreich's Ataxia
CTI-1601, Placebo - Friedreich Ataxia
Phase 2CompletedLarimar Therapeutics, Inc.282022-09-212024-11-29
Gene Therapy for Cardiomyopathy Associated With Friedreich's Ataxia
Low dose LX2006, Mid Dose LX2006, High Dose LX2006 - Friedreich Ataxia, Cardiomyopathy, Secondary
Phase 1 / Phase 2Active not recruitingLexeo Therapeutics82022-08-242025-12-23
Evaluation of the Effect of Artesunate in Friedreich Ataxia (FA)
Artesunate Oral Product - Friedreich Ataxia
Phase 1 / Phase 2CompletedInstitut National de la Santé Et de la Recherche Médicale, France202022-05-062026-05-20
FRDA Investigator Initiated Study (IIS) With Elamipretide
Elamipretide - Friedreich Ataxia
Phase 1 / Phase 2CompletedChildren's Hospital of Philadelphia202022-03-032025-12-12
NAD+ Precursor Supplementation in Friedreich's Ataxia
MIB-626 - Friedreich Ataxia
Phase 2CompletedMetro International Biotech, LLC72021-05-172023-07-17
A Study to Assess the Efficacy and Safety of Vatiquinone for the Treatment of Participants With Friedreich Ataxia
Vatiquinone, Placebo - Friedreich Ataxia
Phase 2 / Phase 3CompletedPTC Therapeutics1462020-12-172026-04-13
Safety and Efficacy of Etravirine in Friedreich Ataxia Patients
Etravirine Tablets - Friedreich Ataxia
Phase 2CompletedIRCCS Eugenio Medea302020-09-172024-12-04
Micronised Resveratrol as a Treatment for Friedreich Ataxia
Resveratrol - Friedreich Ataxia
Phase 2CompletedMurdoch Childrens Research Institute252019-05-232024-05-22
A Clinical Study to Evaluate the Effect of MIN-102 on the Progression of Friedreich's Ataxia in Male and Female Patients
MIN-102, Placebo - Friedreich Ataxia
Phase 2CompletedMinoryx Therapeutics, S.L.392019-03-262022-10-13
Efficacy, Tolerability, and Pharmacokinetics of Multiple Doses of Oral TAK-831 in Adults With Friedreich Ataxia
TAK-831, TAK-831 Placebo - Friedreich Ataxia
Phase 2CompletedNeurocrine Biosciences672017-11-082021-06-14
(+) Epicatechin to Treat Friedreich's Ataxia
(+)-Epicatechin - Friedreich's Ataxia
Phase 2CompletedRalitza Gavrilova102016-09-012019-12-05
Open Trail of γIFN for Friedreich Ataxia
gamma interferon - Friedreich Ataxia
Phase 2CompletedIRCCS Eugenio Medea122016-06-262020-02-26
A First in Human Study of RT001 in Patients With Friedreich's Ataxia
Low dose cohort, High dose cohort - Friedreich's Ataxia
Phase 1 / Phase 2CompletedBiojiva LLC192015-08-012020-11-27
A Study to Learn About the Effects and Safety of RTA 408 (Omaveloxolone) in People Aged 16 to 40 With Friedreich's Ataxia
Omaveloxolone Capsules, 2.5 mg, Omaveloxolone Capsules, 5 mg, Omaveloxolone Capsules, 10 mg - Friedreich Ataxia
Phase 2CompletedBiogen1722015-01-312026-09-03

Showing 20 of 36. Sign in to see all of them.

Narrower conditions

Ataxia (3)  ·  Cardiomyopathies (3)  ·  Cardiomyopathy, Hypertrophic (1)  ·  Cerebellar Ataxia (1)  ·  Heart Diseases (1)  ·  Hypertrophy, Left Ventricular (1)  ·  Mitochondrial Diseases (1)  ·  Rare Diseases (1)  ·  Spinocerebellar Ataxias (1)

Broader conditions

Brain Diseases (36)  ·  Central Nervous System Diseases (36)  ·  Cerebellar Diseases (36)  ·  Congenital, Hereditary, and Neonatal Diseases and Abnormalities (36)  ·  Genetic Diseases, Inborn (36)  ·  Heredodegenerative Disorders, Nervous System (36)  ·  Metabolic Diseases (36)  ·  Nervous System Diseases (36)  ·  Neurodegenerative Diseases (36)  ·  Nutritional and Metabolic Diseases (36)  ·  Spinal Cord Diseases (36)  ·  Spinocerebellar Degenerations (36)  ·  Mitochondrial Diseases (35)  ·  Pathological Conditions, Signs and Symptoms (6)  ·  Dyskinesias (4)

Interventions

alpha-tocotrienol quinone (4)  ·  Deferiprone (2)  ·  Epoetin Alfa (2)  ·  Interferon-gamma (2)  ·  Resveratrol (2)  ·  Catechin (1)  ·  Cohort Studies (1)  ·  Ginkgo biloba extract (1)  ·  Niacinamide (1)  ·  ORF 50 transactivator (1)  ·  RT001 (1)  ·  Riluzole (1)  ·  Varenicline (1)  ·  arginyl-2,'6'-dimethyltyrosyl-lysyl-phenylalaninamide (1)  ·  etravirine (1)

Sponsors

PTC Therapeutics (3)  ·  ApoPharma (2)  ·  Children's Hospital of Philadelphia (2)  ·  Federico II University (2)  ·  IRCCS Eugenio Medea (2)  ·  Larimar Therapeutics, Inc. (2)  ·  Lexeo Therapeutics (2)  ·  Murdoch Childrens Research Institute (2)  ·  University of South Florida (2)  ·  Assistance Publique - Hôpitaux de Paris (1)  ·  Azienda Policlinico Umberto I (1)  ·  Biogen (1)  ·  Biojiva LLC (1)  ·  Design Therapeutics, Inc. (1)  ·  Graviton Bioscience Corporation (1)

Countries

United States (19)  ·  Italy (12)  ·  France (9)  ·  Australia (6)  ·  Spain (6)  ·  Germany (5)  ·  Austria (3)  ·  Belgium (3)  ·  Canada (3)  ·  United Kingdom (3)  ·  Brazil (2)  ·  Czechia (1)  ·  New Zealand (1)

Top investigators

David Lynch, MD, PhD (3)  ·  Arnold Munnich, M.D. (2)  ·  Massimo Pandolfo, M.D. (2)  ·  Alessandro Filla, MD (1)  ·  Alexandra Durr (1)  ·  Andrea Martinuzzi, MD (1)  ·  Arnold Munnich, MD (1)  ·  Carlo Casali, MD (1)  ·  Curtis Scribner, MD (1)  ·  Franco Taroni (1)  ·  Franco Taroni, M.D. (1)

Results publications

PMID 17826341, PMID 20090835, PMID 20599042, PMID 22633670, PMID 22744651, PMID 26321318, PMID 30656180, PMID 32677106, PMID 33068037, PMID 33324899, PMID 36524101, PMID 39201893, PMID 40614535, PMID 40739200, PMID 42307907

NIH funding

2008 (1), 2019 (1)